15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study-Reference-Cited by-同舟云学术

15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study

Published:2023-01-18 Issue: Volume: Page:
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Mei Chen¹²³^ORCID,Ye Li¹²³,Ren Yanling¹²³^ORCID,Zhou Xinping¹²³^ORCID,Ma Liya¹²³,Xu Gaixiang¹²³,Xu Weilai⁴,Lu Chenxi¹²,Yang Haiyang¹²³,Luo Yingwan¹²³,Jiang Lingxu¹²³,Lang Wei¹²³,Zhu HongHu²³,Jin Jie²³^ORCID,Tong Hongyan¹²³⁵

Affiliation:

1. Myelodysplastic Syndromes Diagnosis and Therapy Center the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China

2. Department of Hematology the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China

3. Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment Hangzhou Zhejiang China

4. Department of Hematology Zhejiang Province People's Hospital Hangzhou China

5. Cancer Center Zhejiang University Hangzhou Zhejiang China

Funder

Natural Science Foundation of Zhejiang Province

National Natural Science Foundation of China

Publisher

Wiley

Subject